HK1137931A1 - Long term 24 hour intestinal administration of levodopa/carbidopa 24 / - Google Patents

Long term 24 hour intestinal administration of levodopa/carbidopa 24 /

Info

Publication number
HK1137931A1
HK1137931A1 HK10103896.7A HK10103896A HK1137931A1 HK 1137931 A1 HK1137931 A1 HK 1137931A1 HK 10103896 A HK10103896 A HK 10103896A HK 1137931 A1 HK1137931 A1 HK 1137931A1
Authority
HK
Hong Kong
Prior art keywords
carbidopa
levodopa
long term
intestinal administration
hour
Prior art date
Application number
HK10103896.7A
Other languages
English (en)
Chinese (zh)
Inventor
‧尼霍姆
‧阿斯伯格
‧博爾蘇伊
‧圖奇克-塞特勒
Original Assignee
雅培產品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 雅培產品有限公司 filed Critical 雅培產品有限公司
Publication of HK1137931A1 publication Critical patent/HK1137931A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK10103896.7A 2006-05-31 2010-04-21 Long term 24 hour intestinal administration of levodopa/carbidopa 24 / HK1137931A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80988906P 2006-05-31 2006-05-31
PCT/EP2007/055275 WO2007138086A1 (en) 2006-05-31 2007-05-31 Long term 24 hour intestinal administration of levodopa/carbidopa

Publications (1)

Publication Number Publication Date
HK1137931A1 true HK1137931A1 (en) 2010-08-13

Family

ID=38434843

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103896.7A HK1137931A1 (en) 2006-05-31 2010-04-21 Long term 24 hour intestinal administration of levodopa/carbidopa 24 /

Country Status (16)

Country Link
US (1) US20080051459A1 (xx)
EP (1) EP2063865A1 (xx)
JP (1) JP2009543761A (xx)
KR (1) KR20090057349A (xx)
CN (1) CN101636145B (xx)
AU (1) AU2007267135B2 (xx)
BR (1) BRPI0711882A2 (xx)
CA (1) CA2653683A1 (xx)
HK (1) HK1137931A1 (xx)
IL (1) IL195599A0 (xx)
MX (1) MX2008015339A (xx)
NO (1) NO20085418L (xx)
RU (1) RU2484815C2 (xx)
UA (1) UA95954C2 (xx)
WO (1) WO2007138086A1 (xx)
ZA (1) ZA200810834B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2252284B1 (en) 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
DK2432454T3 (en) * 2009-05-19 2017-06-19 Neuroderm Ltd COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA DECARBOXYLASE INHIBITORS
PL3326615T3 (pl) * 2010-11-15 2020-07-27 Neuroderm Ltd Ciągłe podawanie L-dopy, inhibitorów dekarboksylazy dopy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
EP2653179B1 (en) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System for calculating and administering a drug to a patient with Parkinson's disease
HUE042425T2 (hu) 2012-06-05 2019-06-28 Neuroderm Ltd Apomorfint és szerves savakat tartalmazó készítmények és alkalmazásaik
EP4299128A3 (en) 2014-03-13 2024-04-17 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3782617T3 (pl) 2014-09-04 2024-06-24 Lobsor Pharmaceuticals Aktiebolag Farmaceutyczne kompozycje żelowe zawierające lewodopę, karbidopę i entakapon
PT3209302T (pt) 2014-10-21 2019-07-19 Abbvie Inc Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP3291872A4 (en) 2015-05-06 2019-02-13 SynAgile Corporation PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
US20180021280A1 (en) * 2016-07-20 2018-01-25 Abbvie Inc. Levodopa and Carbidopa Intestinal Gel and Methods of Use
EP3500246B1 (en) 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019166322A1 (en) 2018-03-02 2019-09-06 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
WO2019191353A1 (en) * 2018-03-29 2019-10-03 Riverside Pharmaceuticals Corporation Levodopa fractionated dose composition and use
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CN118765198A (zh) * 2022-01-03 2024-10-11 纽罗德姆有限公司 用于治疗帕金森病的方法和组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
HUP0301465A3 (en) * 2000-06-23 2006-07-28 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
NZ546662A (en) * 2003-10-20 2009-03-31 Teva Pharma Composition and dosage form for sustained effect of levodopa
ZA200610042B (en) * 2004-06-04 2008-06-25 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
US20080020041A1 (en) * 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions

Also Published As

Publication number Publication date
MX2008015339A (es) 2008-12-16
EP2063865A1 (en) 2009-06-03
JP2009543761A (ja) 2009-12-10
ZA200810834B (en) 2010-03-31
BRPI0711882A2 (pt) 2012-01-10
CN101636145A (zh) 2010-01-27
WO2007138086A1 (en) 2007-12-06
NO20085418L (no) 2009-02-26
AU2007267135A1 (en) 2007-12-06
UA95954C2 (ru) 2011-09-26
US20080051459A1 (en) 2008-02-28
RU2008150776A (ru) 2010-07-10
CA2653683A1 (en) 2007-12-06
AU2007267135B2 (en) 2013-03-07
KR20090057349A (ko) 2009-06-05
IL195599A0 (en) 2009-09-01
CN101636145B (zh) 2014-04-23
RU2484815C2 (ru) 2013-06-20

Similar Documents

Publication Publication Date Title
HK1137931A1 (en) Long term 24 hour intestinal administration of levodopa/carbidopa 24 /
IL175314A0 (en) Administration of levodopa and carbidopa
IL186684A0 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
EP1987068A4 (en) MODIFICATION OF OLIGOSACCHARIDES AND MARKING OF PROTEINS
EP2104424A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
EP1924318A4 (en) SYNCHRONIZATION OF REPETITIVE THERAPEUTIC INTERVENTIONS
GB0604535D0 (en) Betulonic acid derivatives
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
PL1994004T3 (pl) 1,4-Dipodstawione pochodne 3-cyjano-pirydonu i ich zastosowanie jako pozytywnych allosterycznych modulatorów receptorów MGLUR2
IL180650A0 (en) Infusion and injection solution of levodopa
WO2011044230A9 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
GB2436421B (en) Timing source
EP2120965A4 (en) N-HALOGENATED AMINO BINDINGS AND DERIVATIVES
HRP20130544T1 (xx) Dugoroäśno lijeäśenje hiv-infekcije sa tcm278
GB0622834D0 (en) Timing source
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
IL194189A0 (en) Combination treatment of metabolic disorders
IL193687A0 (en) Formulations of sitaxsentan sodium
EP2114374A4 (en) PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
ZA200800348B (en) Derivatives of seleno-amino acids
GB0602780D0 (en) Amino Acid Derivatives
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
IL187732A0 (en) Levodopa compositions
GB0601688D0 (en) Cuff fasteners